2nd Edition: Treatment of Bone Metastasis

Dear Colleagues,

This collection is the second edition of a previous Special Issue, entitled "Treatment of Bone Metastasis”(https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Bone_Metastasis).

The incidence of metastatic bone disease is increasing, as patients with cancer are living longer. Bone is the third most common site of metastatic disease, after the lungs and the liver. Long bone metastases are a common presentation in patients with advanced cancer, occurring in up to 70% of patients. In 2008, it was estimated that almost 300,000 patients with advanced cancer in the USA had skeletal metastases. Skeletal metastases can dramatically decrease patients’ quality of life as a result of skeletal related events. In 2006, the financial burden of treating patients with metastatic bone disease in the USA per year was estimated to be approximately 12.6 billion dollars, which accounted for 17% of the total annual cost of cancer treatments. Patients with metastatic bone disease may seek medical care at community hospitals. Traditional management techniques involve a combination of pharmacotherapy, radiotherapy, and surgical procedures. Over the last few decades, advances in medical and surgical treatments have been proposed regarding the management of metastatic bone disease. Considering the limited expectancy of most patients with bone metastases, the main goal of novel medical and less invasive treatments is to improve the quality of life of patients with bone metastases, reducing the adverse effects related to the traditional medical or surgical treatments.

We are pleased to invite the submission of manuscripts focusing on new research on basic, clinical, and surgical research on the treatment of bone metastases.

This Special Issue aims to explore all areas of treatment of bone metastases, including the following:

• Surveillance imaging and diagnostic work to ensure the accurate and timely identification of bone metastases.
• Current systemic treatment options with zolendronic acid and denosumab in order to provide knowledge of innovative techniques in evolving therapies.
• The role of interventional radiology: embolization, electro-chemotherapy, magnetic resonance imaging guided high-intensity focused ultrasound, and thermal ablation therapies.
• The search for possible prognostic factors affecting survival—the life expectancy of patients with bone metastases seems to be the most important factor in determining the surgical treatment, and in avoiding over- or under-treatments.
• The role of surgery: based on the risk of surgical complications, the patient’s prognosis seems to be important regarding the type of surgical treatment in a patient with bone metastases.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: nuclear medicine, radiology, interventional radiology, orthopedics, and oncology.

We look forward to receiving your contributions.

Dr. Costantino Errani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.